Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Jerman

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
British Journal of Pharmacology|March 17, 2001
SB-334867-A: the first selective orexin-1 receptor antagonistD Smart, C Sabido-David, S J Brough, et al.
European Journal of Pharmacology|March 7, 2001
Pharmacological characterisation of human 5-HT2 receptor subtypesJ C Jerman, S J Brough, T Gager, et al.
Neuroscience|October 29, 2003
Orexinergic neurons and barbiturate anesthesiaT Kushikata, K Hirota, H Yoshida, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2001
Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptorJ G Darker, R A Porter, D S Eggleston, et al.
British Journal of Pharmacology|February 29, 2000
The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)D Smart, M J Gunthorpe, J C Jerman, et al.
European Journal of Pharmacology|April 13, 2001
Characterisation using FLIPR of human vanilloid VR1 receptor pharmacologyD Smart, J C Jerman, M J Gunthorpe, et al.
British Journal of Pharmacology|August 1, 1997
Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranesH J Herdon, J C Jerman, T O Stean, et al.
British Journal of Pharmacology|September 28, 1999
Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPRD Smart, J C Jerman, S J Brough, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 1999
Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agentW N Chan, J M Evans, M S Hadley, et al.
Journal of Medicinal Chemistry|November 8, 1996
Synthesis of novel trans-4-(substituted-benzamido)-3,4-dihydro-2H-benzo[b]-pyran-3-ol derivatives as potential anticonvulsant agents with a distinctive binding profileW N Chan, J M Evans, M S Hadley, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
British Journal of Pharmacology|March 17, 2001
SB-334867-A: the first selective orexin-1 receptor antagonistD Smart, C Sabido-David, S J Brough, et al.
European Journal of Pharmacology|March 7, 2001
Pharmacological characterisation of human 5-HT2 receptor subtypesJ C Jerman, S J Brough, T Gager, et al.
Neuroscience|October 29, 2003
Orexinergic neurons and barbiturate anesthesiaT Kushikata, K Hirota, H Yoshida, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2001
Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptorJ G Darker, R A Porter, D S Eggleston, et al.
British Journal of Pharmacology|February 29, 2000
The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)D Smart, M J Gunthorpe, J C Jerman, et al.
European Journal of Pharmacology|April 13, 2001
Characterisation using FLIPR of human vanilloid VR1 receptor pharmacologyD Smart, J C Jerman, M J Gunthorpe, et al.
British Journal of Pharmacology|August 1, 1997
Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranesH J Herdon, J C Jerman, T O Stean, et al.
British Journal of Pharmacology|September 28, 1999
Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPRD Smart, J C Jerman, S J Brough, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 1999
Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agentW N Chan, J M Evans, M S Hadley, et al.
Journal of Medicinal Chemistry|November 8, 1996
Synthesis of novel trans-4-(substituted-benzamido)-3,4-dihydro-2H-benzo[b]-pyran-3-ol derivatives as potential anticonvulsant agents with a distinctive binding profileW N Chan, J M Evans, M S Hadley, et al.
Pageof 3